Comparison

Clinical StudyPal vs INFORMUS

Price, ratings, monetisation and update history for both apps, side by side — with what reviewers say about each.

Head to head
About

Clinical StudyPal

This app helps patients manage their clinical trial participation by collecting electronic patient-reported outcomes, managing study visits, and providing easy access to all necessary documentation.

Highlights
  • ePRO/eCOA/eDiary collection
  • Study visit management
  • Access to study documentation
  • Patient-centric design
Features
Read full description

Clinical StudyPal is designed for patients to help gather their ePRO/eCOA/eDiary, manage their study visits, and have all study documentation available at their fingertips

About

INFORMUS

This app helps clinical trial participants manage their study information, including treatment plans, appointments, and payments. It allows users to track daily dosage results and access helpful study resources through a user-friendly interface.

Highlights
  • Access treatment plans and appointments
  • View payment information
  • Track daily dosage results
  • Access study information
  • User-friendly interface
Features
Read full description

INFORMUS’ user-friendly interface provides easy access to study information, dosage and appointment reminders, payments and more!   Enhance your study experience with one simple app: • Access treatment plan and appointments • Access to payment information • Enter and track your daily dosage results • Access to helpful study information   Stay engaged with your study using INFORMUS. *This app is for clinical participants only.*

Screenshots

Clinical StudyPal3 screens
INFORMUS4 screens

Verdict

The call

The clearest difference is rating: Clinical StudyPal at 5.0 against INFORMUS's 4.3. INFORMUS's advantage is ratings volume (8 vs 2). On price, update cadence, ads and in-app purchases there is nothing between them.

Scored on Price · Rating · Positive reviews · Number of ratings · Update frequency · Ads · In-app purchases · Monetization · Best chart rank · Devices · Requires iOS

CostPrice · In-app purchases · Ads · Monetization

Both are free to download. Neither carries in-app purchases, so what you see is what you pay.

ReceptionRating · Positive reviews · Number of ratings

Clinical StudyPal holds the better App Store score, 5.0 against 4.3. Both are backed by a comparable volume of ratings — 2 and 8 respectively.

UpkeepUpdate frequency

Clinical StudyPal ships an update every 6 weeks, INFORMUS monthly. The most recent releases landed on October 15, 2026 and October 7, 2026 respectively.

Scorecard2 real differences · 7 level
Clinical StudyPal versus INFORMUS: the parameters behind the verdict, then further details
ParameterClinical StudyPalINFORMUS
PriceFreeFree
Rating5.0 (2 ratings) — better4.3 (8 ratings)
Number of ratings28 — better
Update frequencyEvery 6 weeksMonthly — better
AdsNoNo
In-app purchasesNoNo
MonetizationFreeFree
DevicesiPhone, iPodiPhone, iPod
Requires iOS15.615.1 — better
Further details — not scored
Size198 MB46 MB
Age rating12+17+
DeveloperStudy PalCaerus Marketing Group LLC

Customer experience

Clinical StudyPal

All ratings2 ratings
Positive100.0%
Neutral0.0%
Negative0.0%

INFORMUS

All ratings8 ratings
Positive75.0%
Neutral12.5%
Negative12.5%

In-app purchases

None

Clinical StudyPal

No in-app purchases

None

INFORMUS

No in-app purchases

Questions

Is Clinical StudyPal free?
Clinical StudyPal is free to download, with no in-app purchases.
Is INFORMUS free?
INFORMUS is free to download, with no in-app purchases.
Which has better reviews, Clinical StudyPal or INFORMUS?
Clinical StudyPal is rated higher. Clinical StudyPal averages 5.0 out of 5 from 2 ratings, while INFORMUS averages 4.3 from 8 ratings.
Do Clinical StudyPal or INFORMUS have ads?
Neither Clinical StudyPal nor INFORMUS shows ads.
Which is updated more often, Clinical StudyPal or INFORMUS?
Clinical StudyPal ships an update every 6 weeks, and INFORMUS monthly. Most recently, Clinical StudyPal was updated on October 15, 2026 and INFORMUS on October 7, 2026.

Other comparisons